Bookmarks

Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II)

Population Size

Not reported
Population Size statistic card

Years

1970

Years statistic card

Associated BioSamples

None/not available

Associated BioSamples statistic card

Geographic coverage

United Kingdom

Scotland

Geographic coverage statistic card

Lead time

1-2 months

Lead time statistic card

Summary

Population-level surveillance and rapid assessment of the effectiveness of therapeutic or preventive interventions are required to ensure that interventions are targeted to those at highest risk of serious illness or death from COVID-19.

Documentation

Introduction: Following the emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019 and the ensuing COVID-19 pandemic, population-level surveillance and rapid assessment of the effectiveness of existing or new therapeutic or preventive interventions are required to ensure that interventions are targeted to those at highest risk of serious illness or death from COVID-19. We aim to repurpose and expand an existing pandemic reporting platform to determine the attack rate of SARS-CoV-2, the uptake and effectiveness of any new pandemic vaccine (once available) and any protective effect conferred by existing or new antimicrobial drugs and other therapies.

Methods and analysis: A prospective observational cohort will be used to monitor daily/weekly the progress of the COVID-19 epidemic and to evaluate the effectiveness of therapeutic interventions in approximately 5.4?million individuals registered in general practices across Scotland. A national linked dataset of patient-level primary care data, out-of-hours, hospitalisation, mortality and laboratory data will be assembled. The primary outcomes will measure association between: (A) laboratory confirmed SARS-CoV-2 infection, morbidity and mortality, and demographic, socioeconomic and clinical population characteristics; and (B) healthcare burden of COVID-19 and demographic, socioeconomic and clinical population characteristics. The secondary outcomes will estimate: (A) the uptake (for vaccines only); (B) effectiveness; and (C) safety of new or existing therapies, vaccines and antimicrobials against SARS-CoV-2 infection. The association between population characteristics and primary outcomes will be assessed via multivariate logistic regression models. The effectiveness of therapies, vaccines and antimicrobials will be assessed from time-dependent Cox models or Poisson regression models. Self-controlled study designs will be explored to estimate the risk of therapeutic and prophylactic-related adverse events.

https://bmjopen.bmj.com/content/10/6/e039097

Dataset type

Health and disease

Dataset sub-type

Not applicable

Keywords

Provenance

Image contrast

Not stated

Biological sample availability

None/not available

Details

Publishing frequency

Monthly

Version

1.0.0

Modified

08/10/2024

Citation Requirements

Public Health Scotland

Coverage

Start date

01/01/1970

Time lag

Not applicable

Geographic coverage

United Kingdom, Scotland

Maximum age range

150

Accessibility

Language

en

Controlled vocabulary

READ, ICD10

Format

Excel Files, R Files

Data Access Request

Dataset pipeline status

Not available

Time to dataset access

1-2 months

Data Controller

EAVEII team

Data Processor

EAVEII team

Dataset Types: Health and disease


Collection Sources:

Relationships:

end of page